Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
The NYSE-listed firm hiked its 2017 adjusted earnings per share prediction to US$9.75, up from a previous estimate of between US$9.45 and US$9.55 per share
Morgan Stanley analyst Matthew Harrison said: "We expect continued topline beats to drive near-term upside as Sarepta's underappreciated pipeline drives long-term optionality”
The company completed the placing this morning, after an accelerated bookbuild, with 1.757576mln new ordinary shares issued at a price of 165p each
Indivior filed patent lawsuits against Mylan, among others, after a Delaware court issued a ruling at the beginning of September finding that Indian generics firm Dr Reddy's Laboratories Inc had not infringed the UK firm’s patents for the product
Dr Annalisa Jenkins will succeed Dr. Stephen Parker, the company's non-executive chairman since September 2015 with effect from today
The biopharma company said MoveDMD demonstrated improved efficacy across all key assessments and, in addition, supportive changes in measures of muscle health were seen
Indivior also said it had made an US$12.5mln up-front payment to Durect Corporation for "certain patent rights" to improve protection of RBP-7000, an injectable version of antipsychotic medication risperidone
The AIM-listed digital technologies company said the contract is for a Phase II clinical trial evaluating the safety and tolerability of a novel treatment for patients with Huntington's disease.